Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

Journal of Virology

Volumn 75, Issue 16, 2001, Pages 7435-7452

  Crotty, S ^a   Miller, C J ^a   Lohman, B L ^a   Neagu, M R ^a   Compton, L ^a   Lu, D ^a   Lu, F X S ^a   Fritts, L ^a   Lifson, J D ^a   Andino, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; NEF PROTEIN; POL PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MACACA; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VAGINA; VIREMIA; VIRUS VIRULENCE;

ANIMALS; ARENAVIRUSES, NEW WORLD; FEMALE; GENETIC VECTORS; HUMANS; MACACA; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VIRAL VACCINES;

EID: 0034910934     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.16.7435-7452.2001     Document Type: Article

References (82)

1. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus
2. Attenuated Mengo virus: A new vector for live recombinant vaccines
3. Engineering poliovirus as a vaccine vector for the expression of diverse antigens
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
6. Prime-boost immunization strategies against HIV
7. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
8. Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction
9. mac251: Dependence on route of challenge exposure
10. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
11. Cytokine production in motor neurons by poliovirus replicon vector gene delivery
12. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
13. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
14. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
15. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection
16. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
17. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection
18. The polio eradication effort: Should vaccine eradication be next?
19. Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees
20. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
21. pol): Structural, biochemical, and biological analysis of conserved structural motifs A and B
22. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime
23. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
24. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
25. Expression of an antigenic adenovirus epitope in a group B coxsackievirus
26. Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): Evidence for CD4-associated molecules required for infection
27. Paralytic poliomyelitis: Seasoned strategies, disappearing disease
28. gag and cholera toxin adjuvant induces Th1/Th2 help for virus specific immune responses in reproductive tissues
29. Protective immunity induced by live attenuated simian immunodeficiency virus
30. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus
31. An infectious cDNA clone of the poliovirus Sabin strain could be used as a stable repository and inoculum for the oral polio live vaccine
32. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
33. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus
34. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient post-inoculation antiretroviral treatment
35. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay
36. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle
37. Simian immunodeficiency virus DNA vaccine trial in macaques
38. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251
39. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors
40. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen
41. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac
42. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
43. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases
44. +-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV
45. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses
46. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
47. Poliovirus
48. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239Δ3 in adult and infant rhesus monkeys
49. Recombinant viruses as vectors for mucosal immunity
50. Expression of foreign proteins by poliovirus polyprotein fusion: Analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames
51. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
52. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome
53. Formation and function of poliovirus antibody in different tissues
54. Cloned infectious complementary DNA of the poliovirus Sabin 1 genome: Biochemical and biological properties of the recovered virus
55. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
56. Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan eskimos
57. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
58. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines
59. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine
60. It is too early to stop polio vaccination
61. Genetic stability of Sabin 1 strain of poliovirus: Implications for quality control of oral poliovirus vaccine
62. IgG surfaces as an important component in mucosal protection
63. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
64. Live attenuated AIDS viruses as vaccines: Promise or peril?
65. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge
66. + lymphocytes
67. Using recombinant vectors as HIV vaccines
68. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
69. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice
70. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
71. Live attenuated polio-virus vaccines
72. Toward a poliovirus-based simian immunodeficiency virus vaccine: Correlation between genetic stability and immunogenicity
73. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions
74. Polioviruses and mucosal vaccines
75. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge
76. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice